Evaluating a new injectable contraceptive for women
CENTRAL LABORATORY FOR PHARMACOKINETIC/PHARMACODYNAMIC EVALUATION OF LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION
['FUNDING_OTHER'] · OREGON HEALTH & SCIENCE UNIVERSITY · NIH-11177579
This study is testing a new long-lasting birth control shot called levonorgestrel butanoate, especially for women who are overweight and at risk for blood clots, to see if it can be a safer and easier option than traditional methods.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OREGON HEALTH & SCIENCE UNIVERSITY (nih funded) |
| Locations | 1 site (PORTLAND, UNITED STATES) |
| Trial ID | NIH-11177579 on ClinicalTrials.gov |
What this research studies
This research investigates a new long-acting injectable contraceptive called levonorgestrel butanoate, designed specifically for women, particularly those who are obese and at risk for venous thromboembolism (VTE). The study aims to provide a safer, estrogen-free alternative to traditional contraceptive methods, which often require strict adherence. By conducting a clinical trial, the research will assess the effectiveness and safety of this new contraceptive formulation, potentially offering a more convenient option for women seeking reliable birth control. Participants will be monitored for adherence and any side effects during the trial.
Who could benefit from this research
Good fit: Ideal candidates for this research are women, particularly those who are obese and seeking effective contraception without the risks associated with estrogen.
Not a fit: Patients who are not seeking contraception or those who do not have concerns related to obesity or VTE may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective contraceptive option for women, especially those at higher risk for VTE.
How similar studies have performed: Previous research has shown success with other long-acting contraceptive methods, but this specific formulation is novel and aims to address a unique patient population.
Where this research is happening
PORTLAND, UNITED STATES
- OREGON HEALTH & SCIENCE UNIVERSITY — PORTLAND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: EDELMAN, ALISON — OREGON HEALTH & SCIENCE UNIVERSITY
- Study coordinator: EDELMAN, ALISON
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.